aiwiki.page
English
Health / Medicine & Treatment / brachytherapy

Brachytherapy

Brachytherapy treats cancer by placing radiation sources within or close to a tumour, delivering a concentrated dose while limiting exposure of surrounding tissues.

26 keywords7 linked from2 not yet writtenWritten by AI
Radiation Therap…Prostate cancerX-ray Computed T…Magnetic Resonan…PhotonDNAIsotopeDiagnosisBrachyther…

Brachytherapy is a form of radiation therapy in which a radiation source is placed inside, on the surface of, or immediately beside the tissue being treated. Its name derives from the Greek brachys, meaning “short,” referring to the short distance between source and target. Most clinical brachytherapy uses encapsulated radioactive sources, although some systems generate low-energy X-rays electronically. Unlike external-beam radiotherapy, which directs radiation into the body from a machine at a distance, brachytherapy creates a highly localized radiation field from within or next to the target.

The technique is particularly important in the treatment of cervical and prostate cancer, and it also has established applications in selected breast, skin, ocular, vaginal, and other cancers. It may constitute the entire radiation treatment, provide a concentrated additional dose after external-beam treatment, or relieve symptoms. Its principal advantage is a steep decrease in dose with distance from the source, allowing a high tumour dose while limiting irradiation of more distant healthy tissues. That advantage depends on accurate source placement: small changes in the relationship between source, tumour, and nearby organs can substantially alter the delivered dose.

Modern brachytherapy combines procedural medicine, imaging, radiation physics, and computerized treatment planning. Its clinical effects depend not only on the total radiation dose but also on source geometry, dose rate, treatment duration, tumour characteristics, and the sensitivity of surrounding organs. Temporary implants, permanent radioactive seeds, and remotely controlled moving sources therefore represent related but distinct treatment methods.

Historical development

Brachytherapy emerged shortly after the discoveries of X-rays in 1895 and radioactivity in 1896. The isolation of radium by Marie and Pierre Curie in 1898 provided an intense radioactive material that could be placed near diseased tissue. Early twentieth-century clinicians investigated radium for skin lesions and cancers accessible through natural body openings. These treatments developed before modern radiation dosimetry, and both patients and staff sometimes received poorly characterized exposures. Nevertheless, the ability to deliver radiation directly to a lesion established a therapeutic approach distinct from treatment with external X-ray equipment.

Radium needles and tubes became widely used for interstitial and intracavitary treatment. Clinical centres developed reproducible arrangements of sources to improve dose uniformity and make prescriptions more comparable. The Stockholm and Paris approaches were influential in gynaecological treatment. In Manchester, Ralston Paterson and Herbert Parker developed dosage rules during the 1930s for arranging sources in geometrically defined implants. Margaret Tod and William Meredith subsequently developed the Manchester system for cervical treatment, including the reference location known as point A. These systems translated source strength, treatment time, and implant geometry into practical treatment prescriptions before three-dimensional imaging was available.

Artificial radionuclides progressively replaced radium during the second half of the twentieth century. Caesium-137 was used extensively for low-dose-rate intracavitary treatment, while iridium-192 became important for interstitial implants and remote afterloading. These developments reduced reliance on radium, whose handling presented problems associated with its long half-life, radiation emissions, and potential contamination. Afterloading further changed clinical practice: applicators or empty catheters could first be positioned without radioactive material present, and sources could then be introduced after placement had been checked. Remote afterloading allowed staff to leave the treatment room before irradiation began.

Imaging and computing produced another major transformation. Two-dimensional radiographs originally documented source positions and anatomical reference points. Computed tomography later enabled volumetric reconstruction of implants, while magnetic resonance imaging improved visualization of cervical tumours and adjacent soft tissues. Three-dimensional planning shifted attention from standard source patterns toward the actual dose received by a defined tumour volume and nearby organs. Contemporary image-guided adaptive brachytherapy adjusts treatment to anatomy and tumour response, rather than assuming that a single geometric prescription adequately represents every patient.

Physical and biological principles

The spatial concentration of dose is the defining physical property of brachytherapy. For an ideal point source in a uniform medium, geometric spreading makes radiation intensity decrease approximately with the inverse square of distance. Doubling the distance would therefore reduce the intensity to roughly one quarter before accounting for attenuation and scattering. Real sources have finite dimensions, encapsulation, and direction-dependent emissions, so clinical calculations require more detailed models. Nevertheless, the distance effect explains both the technique’s ability to spare distant tissues and its sensitivity to millimetre-scale errors near a source.

Radiation deposits energy in tissue through interactions involving photons or charged particles. The resulting ionization can damage DNA directly or indirectly through reactive chemical species produced by water radiolysis. Complex DNA damage, including double-strand breaks, can prevent tumour cells from retaining their reproductive capacity. Normal tissues are also affected, and their tolerance depends on cell type, tissue organization, irradiated volume, and the time available for repair. Brachytherapy is therefore not intrinsically selective for malignant cells; its selectivity comes mainly from where the dose is delivered.

Absorbed dose is measured in gray, with 1 Gy=1 J/kg1\ \mathrm{Gy}=1\ \mathrm{J/kg}. Equal physical doses do not necessarily produce equal biological effects when given at different rates or in different numbers of treatments. A continuously delivered low dose allows repair of some radiation damage during exposure. A large dose delivered over minutes has a different effect, particularly in normal tissues that develop late injury. In fractionated treatment, the linear–quadratic model commonly expresses biological effect through the biologically effective dose:

BED=nd(1+dα/β),\mathrm{BED}=nd\left(1+\frac{d}{\alpha/\beta}\right),

where nn is the number of fractions, dd is the dose per fraction, and α/β\alpha/\beta characterizes the tissue’s fractionation response. Continuous irradiation requires additional treatment of repair during exposure.

A related quantity, the equivalent dose in 2-Gy fractions, or EQD2, permits approximate comparison or combination of different schedules. This is especially important when external-beam treatment and brachytherapy contribute to the same course. The calculation depends on assumptions about tissue sensitivity and repair, and it is not a direct measurement of biological injury. Differences in irradiated volume, spatial dose distribution, and treatment timing remain important. For example, adding two maximum point doses from different treatment sessions may misrepresent the cumulative exposure if those maxima occur in different pieces of tissue.

Sources, dose rates, and treatment delivery

Brachytherapy sources are selected according to their radiation energy, half-life, physical size, and intended application. An isotope with a short half-life loses activity relatively quickly, affecting both treatment duration and replacement schedules. Iridium-192, widely used in remote afterloaders, has a half-life of about 74 days and emits photons with a spectrum averaging roughly 0.38 MeV. Cobalt-60 has a half-life of about 5.27 years and emits higher-energy photons. Its longer useful source life reduces replacement frequency, although the higher energy affects shielding requirements. Source choice therefore influences clinical equipment and service organization as well as dose distribution.

Permanent prostate implants commonly use iodine-125 or palladium-103 seeds; caesium-131 is another available source. Their approximate physical half-lives are 59 days, 17 days, and 9.7 days, respectively. The small encapsulated seeds remain in the body while their activity declines. Low photon energies help confine much of the dose to the implanted region. Other applications use different sources: ruthenium-106 eye plaques deliver predominantly beta radiation, whereas iodine-125 plaques emit low-energy photons. The penetration characteristics of these emissions affect the lesion depths and geometries for which they are used.

Conventional dose-rate categories distinguish low-dose-rate treatment, approximately 0.4–2 Gy per hour, medium-dose-rate treatment, 2–12 Gy per hour, and high-dose-rate treatment, above 12 Gy per hour. These categories describe the dose rate at a specified reference location, not an identical rate throughout the implant. High-dose-rate treatment usually delivers each fraction over minutes with a small source driven through a series of programmed positions. Low-dose-rate treatment may involve temporary exposure over many hours or continuous irradiation from permanent seeds. Pulsed-dose-rate treatment delivers repeated short exposures, often at hourly intervals, to reproduce aspects of continuous low-dose-rate irradiation.

In a remote afterloader, a shielded machine stores the source and moves it through transfer tubes into applicator channels. The programmed stopping locations are called dwell positions, and the time spent at each location is the dwell time. Changing these times reshapes the dose distribution without changing the applicator itself. Temporary sources return to the shielded unit after treatment, leaving no treatment source in the patient. Electronic brachytherapy instead uses a miniature X-ray generator, so radiation production stops when electrical power is removed. Its energy spectrum, dosimetry, and clinical evidence differ from those of radionuclide-based systems; the methods are not automatically interchangeable.

Implantation, imaging, and treatment planning

Brachytherapy procedures are classified partly by how the source reaches the target. Intracavitary treatment places an applicator within a body cavity, such as the uterus and vagina. Interstitial treatment places needles or catheters directly into tissue. Surface treatment uses a mould, applicator, or plaque against a lesion, while intraluminal treatment places a source within a tubular structure such as a bronchus or oesophagus. Some implants combine approaches, particularly when a cavity-based applicator alone cannot adequately cover an irregular tumour. The route is determined by target anatomy and the relationship to sensitive adjacent structures.

Preparation integrates diagnosis, tumour extent, prior treatments, and procedural feasibility. Biopsy establishes histology, while examination and imaging define the anatomical setting. Implant placement may require local, regional, or general anaesthesia, depending on the site and complexity. Ultrasound provides real-time guidance for prostate needle placement; CT and MRI are important for reconstructing applicators and evaluating the treated volume. Images acquired with the applicator in place are particularly valuable because insertion can displace or deform the tumour and surrounding organs. Imaging before insertion alone cannot fully describe the treatment geometry.

Planning begins with delineation of target volumes and organs at risk, followed by reconstruction of source channels or individual seeds. Computer calculations generate a three-dimensional dose distribution. A dose–volume histogram summarizes how much of a structure receives a given dose, allowing the plan to be described by reproducible metrics. For example, D90D_{90} is the dose received by at least 90% of a specified volume, while V100V_{100} is the volume or percentage receiving at least the prescription dose. For an organ at risk, D2cm3D_{2\mathrm{cm}^3} describes the minimum dose to its most highly irradiated 2 cubic centimetres. Such measures complement rather than replace inspection of the spatial dose pattern.

Inverse planning algorithms can select dwell times that balance tumour coverage against normal-tissue exposure, but their output depends on the quality of contouring, reconstruction, and optimization settings. A mathematically favourable plan cannot compensate for inadequate catheter placement. Conventional calculation methods often approximate the patient as water, whereas model-based methods can account for tissue composition, air cavities, shielding, and applicator materials. Before delivery, independent checks address source strength, channel connections, programmed positions, and the correspondence between the plan and the actual implant. Anatomy can change between fractions, so repeated imaging or verification may be needed to maintain the intended relationship between sources and tissues.

Cervical and other gynaecological cancers

Brachytherapy is a central component of definitive radiation treatment for many patients with locally advanced cervical cancer. External-beam radiation treats the pelvis and, when appropriate, regional nodal areas; concurrent chemotherapy commonly includes cisplatin. Brachytherapy then delivers a high central dose to the cervix and residual tumour without exposing the entire pelvis to that dose. Its sharp dose gradient is especially valuable because the bladder, rectum, sigmoid colon, and small bowel lie close to the target. Replacing this component with additional external-beam irradiation is not assumed to provide equivalent dose distributions or clinical outcomes.

A conventional intracavitary implant uses a uterine tandem together with vaginal ovoids or a ring. The tandem follows the uterine canal, while the vaginal component positions sources around the cervix. For more extensive or asymmetric disease, interstitial needles can supplement the intracavitary arrangement. This combined technique extends dose coverage into tissue that lies beyond the reach of a standard applicator. The geometry is clinically consequential: simply increasing dwell times in a poorly fitting intracavitary implant may increase bladder or rectal exposure without adequately covering lateral tumour extension.

Image-guided adaptive treatment distinguishes residual visible disease from surrounding tissues at risk of microscopic involvement and incorporates information about the tumour’s initial extent. MRI is particularly useful for cervical soft-tissue assessment, although CT-based planning is also used. The high-risk clinical target volume is evaluated with volumetric dose measures, while adjacent organs are assessed using small-volume dose metrics. The prospective multicentre EMBRACE-I study, reported in 2021, documented approximately 92% five-year local control with MRI-guided adaptive brachytherapy in a large cohort treated for locally advanced cervical cancer. That result describes a defined treatment programme and population rather than a universal outcome for every stage or clinical setting.

Other gynaecological applications involve different targets and objectives. After surgery for selected endometrial cancers, vaginal brachytherapy irradiates the vaginal cuff, a common site of local recurrence. A cylinder applicator can treat this limited region while avoiding much of the bowel exposure associated with pelvic external-beam radiation. The PORTEC-2 randomized trial, involving 427 patients with high-intermediate-risk endometrial cancer, reported five-year vaginal recurrence rates of 1.8% with vaginal brachytherapy and 1.6% with pelvic external-beam treatment, with less gastrointestinal toxicity in the brachytherapy group. Interstitial techniques are also used for selected primary vaginal cancers and local recurrences, where previous irradiation and proximity to bladder or bowel make dose reconstruction particularly important.

Prostate cancer

Prostate brachytherapy uses either permanent low-dose-rate seeds or temporary high-dose-rate catheters. It may be used alone in selected localized cancers or as a boost combined with external-beam radiation. Treatment allocation depends on disease risk, prostate anatomy, urinary function, prior procedures, and the feasibility of an implant. The implant treats a local volume; it does not substitute for management of disease outside that volume. Consequently, tumour stage, grade, prostate-specific antigen concentration, and the estimated likelihood of extension beyond the gland influence how brachytherapy is incorporated into a broader treatment course.

Permanent implantation generally places multiple radioactive seeds through needles introduced through the perineum under transrectal ultrasound guidance. Planning can occur before the procedure or be adapted during implantation. Seeds may be deposited individually or linked in strands, and their final distribution determines target coverage and the dose to the urethra and rectum. Because implantation causes swelling and the seeds may not occupy exactly their planned locations, post-implant imaging is used to evaluate the delivered geometry. This assessment is not merely a record of seed number: a similar number of seeds can produce substantially different dose distributions depending on their positions.

High-dose-rate prostate brachytherapy places temporary transperineal catheters through the gland. An afterloader then moves the source through the catheters, with dwell times optimized to cover the prostate while limiting exposure of the urethra, bladder, and rectum. All sources are removed at the end of treatment, and the catheters are removed after the required fractions. The ability to alter dwell positions and times offers flexibility, but catheter displacement between imaging and delivery can change the actual distribution. Treatment schedules vary, and physical dose cannot be compared across schedules without considering fraction size and biological effect.

Randomized evidence demonstrates the potential for a brachytherapy boost to improve biochemical disease control in some higher-risk settings, while also illustrating toxicity trade-offs. In ASCENDE-RT, 398 men received pelvic irradiation and androgen-deprivation therapy before either a low-dose-rate brachytherapy boost or a dose-escalated external-beam boost. Reported nine-year biochemical progression-free survival was approximately 83% versus 62%, respectively, but severe urinary toxicity was more frequent with the brachytherapy boost. Biochemical recurrence, usually defined using changes in prostate-specific antigen after radiotherapy, is not identical to symptomatic progression or overall survival. Urinary obstruction, retention, urethral narrowing, rectal injury, and erectile dysfunction are among the clinically relevant outcomes, and their frequency depends on baseline function, technique, combined treatments, and follow-up duration.

Breast, eye, skin, and other applications

In breast cancer, brachytherapy can irradiate the tissue around a lumpectomy cavity, where many local recurrences arise. Multicatheter interstitial implants distribute sources through the surrounding breast, whereas balloon or other intracavitary devices position source channels within or around the surgical cavity. These approaches can deliver accelerated partial-breast irradiation over a shorter course than historical whole-breast schedules. Their suitability depends on pathological and anatomical features, including tumour size, margin status, nodal findings, and the distance between the applicator and skin or chest wall. Evidence from a particular technique or selected trial population does not establish equivalence for every partial-breast device or patient group.

For ocular tumours, a radioactive plaque can be sutured to the outer surface of the eye overlying the lesion. The plaque directs radiation toward the tumour while limiting exposure elsewhere. Iodine-125 plaques are used for uveal melanoma, and ruthenium-106 plaques are used in appropriate lesions, with their more limited penetration affecting tumour-depth considerations. The Collaborative Ocular Melanoma Study randomized 1,317 patients with medium-sized choroidal melanoma to iodine-125 plaque treatment or removal of the eye and found no significant survival difference. Eye preservation does not necessarily mean preservation of useful vision: radiation injury to the retina, macula, optic nerve, or lens can occur depending on tumour location and dose.

Surface moulds and applicators provide another use in selected skin cancers, especially where a localized radiation field can conform to a curved surface. Interstitial implantation may be used for thicker or more irregular lesions. Clinical dosimetry must account for source-to-skin distance, surface contour, applicator contact, and the depth of disease. A small air gap or an incorrect depth assumption can materially change the target dose. Some electronic brachytherapy systems have been used for superficial lesions, but their outcomes and long-term evidence must be evaluated separately from established radionuclide techniques and from surgery.

Other applications include selected cancers of the lip, oral cavity, and other head-and-neck sites, as well as bronchial or oesophageal lesions. Intraluminal treatment can place a high dose near a tumour causing obstruction, sometimes as part of palliative care, but proximity to delicate walls and major vessels creates risks such as ulceration, stenosis, or bleeding. Interstitial brachytherapy is also used in specialized settings for soft-tissue sarcoma and other localized tumours. Outside oncology, intravascular brachytherapy has been used to inhibit recurrent tissue growth within coronary stents. That application seeks to suppress proliferating vascular tissue rather than eradicate a malignant tumour.

Adverse effects, radiation protection, and quality assurance

Complications arise from both implantation and radiation exposure. Procedural effects can include bleeding, infection, anaesthesia-related events, and injury from needles or applicators. Radiation-related effects depend on the treated site: pelvic treatment may cause urinary frequency, bowel irritation, vaginal inflammation, or fatigue, while breast treatment may produce tenderness and localized skin changes. Acute reactions often reflect injury to rapidly renewing tissues. Their timing and severity differ from late effects, which can emerge months or years later and may persist after the initial treatment reaction has resolved.

Late injury can involve fibrosis, tissue narrowing, ulceration, necrosis, or damage to small blood vessels. Pelvic irradiation can occasionally produce fistulas between adjacent organs, while eye-plaque treatment can cause radiation retinopathy or optic neuropathy. Dose per fraction, the volume of normal tissue exposed, previous irradiation, and the relation of the source to sensitive structures all influence risk. High-dose regions immediately around sources are expected features of many implants, but their location matters: a high dose within tumour tissue has a different clinical implication from an equally high dose in the urethra or bowel wall.

Radiation-protection requirements differ sharply between temporary and permanent treatment. Once a temporary radioactive source has returned to its shielded storage position, that source no longer irradiates the patient or surrounding people. Permanent implants continue to emit radiation as their activity decays, so discharge procedures address measured exposure levels, source accountability, and locally defined precautions. These controls are particularly relevant to close contact involving children or pregnancy. Encapsulation normally contains the radioactive material; routine exposure from an intact seed is therefore different from contamination caused by a damaged or lost source.

Patient safety depends on a chain of checks rather than a single machine test. Source strength is verified by measurement, applicator dimensions and transfer paths are checked, and the treatment plan is reviewed against the intended implant. High-dose-rate systems include door interlocks, radiation monitors, and mechanisms intended to retract the source if delivery is interrupted. Emergency procedures address the uncommon possibility of a source failing to return to its safe. Independent plan review, confirmation of channel connections, verification of applicator position, and a post-treatment radiation survey address different failure modes. Because the radiation field changes rapidly with distance, a small reconstruction or connection error can have a disproportionately large dosimetric effect.

Clinical evidence, outcome assessment, and service provision

Evidence for brachytherapy must be interpreted by disease site, technique, and treatment objective. A randomized controlled trial comparing vaginal brachytherapy with pelvic irradiation answers a different question from one comparing a prostate implant boost with an external-beam boost. Trials may also differ in imaging quality, source technology, dose schedule, and accompanying systemic treatment. Historical outcomes from two-dimensional planning do not necessarily describe contemporary image-guided practice. Conversely, a technical improvement in dose conformity does not by itself establish a survival advantage or a reduction in clinically important complications.

Endpoints include local tumour control, regional or distant recurrence, disease-specific survival, overall survival, and treatment toxicity. Some endpoints have site-specific limitations: prostate biochemical recurrence can precede clinical progression by years, while eye preservation may coexist with major visual impairment. Patient-reported outcomes capture urinary, bowel, sexual, and other functional effects that clinician toxicity grades may not fully describe. Long follow-up is essential because local recurrence and radiation injury can occur well after treatment. Comparisons also require attention to competing causes of death and differences in baseline health between treatment groups.

Observational studies are important where randomized evidence is limited, particularly for uncommon tumours and technically specialized procedures. However, patients selected for brachytherapy may differ systematically from those receiving other treatments in age, tumour extent, functional status, or access to specialist care. Statistical adjustment can reduce some measured differences but cannot remove every source of bias. Multicentre registries and prospective protocols provide information about reproducibility, uncommon adverse events, and outcomes beyond individual expert institutions. Detailed reporting of implant quality and dose metrics helps distinguish a limitation of the technique from a limitation of its implementation.

Service provision requires a coordinated health-system infrastructure: trained radiation oncologists, medical physicists, radiation therapists, nursing staff, procedural facilities, imaging, anaesthesia support, and regulated source handling. Radioactive-source replacement, equipment maintenance, staff training, and access to applicators are recurring requirements rather than one-time installation costs. These demands are especially consequential in cervical cancer, where a complete definitive radiation course commonly depends on brachytherapy capacity. Transport, referral pathways, and the concentration of expertise can affect whether treatment is completed on time. Research into automated contouring, improved applicators, model-based dose calculation, and adaptive planning therefore intersects with practical questions of staffing, quality assurance, and reliable access.